Pancreatic and Hepatic Injury in COVID-19: A Worse Prognosis in NAFLD Patients?
Cargando...
Archivos
Fecha
2024
Autores
Mengual-Moreno, Edgardo
Nava, Manuel
Manzano, Alexander
Ariza, Daniela
D'MARCO, LUIS
Castro, Ana
Marquina, María A.
Corredor Pereira, Carlos
Checa-Ros, Ana
Bermudez, Valmore
Título de la revista
ISSN de la revista
Título del volumen
Editor
MDPI
Resumen
The novel disease produced by SARS-CoV-2 mainly harms the respiratory tract, but it has shown the capacity to affect multiple organs. Epidemiologic evidence supports the relationship between Coronavirus Disease 2019 (COVID-19) and pancreatic and hepatic injury development, identified by alterations in these organ function markers. In this regard, it is important to ascertain how the current prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) might affect COVID-19 evolution and complications. Although it is not clear how SARS-CoV-2 affects both the pancreas and the liver, a multiplicity of potential pathophysiological mechanisms seem to be implicated; among them, a direct viral-induced injury to the organ involving liver and pancreas ACE2 expression. Additionally, immune system dysregulation, coagulopathies, and drugs used to treat the disease could be key for developing complications associated with the patient’s clinical decline. This review aims to provide an overview of the available epidemiologic evidence regarding developing liver and pancreatic alterations in patients with COVID-19, as well as the possible role that NAFLD/NASH might play in the pathophysiological mechanisms underlying some of the complications associated with COVID-19. This review employed a comprehensive search on PubMed using relevant keywords and filters. From the initial 126 articles, those aligning with the research target were selected and evaluated for their methodologies, findings, and conclusions. It sheds light on the potential pathophysiological mechanisms underlying this relationship. As a result, it emphasises the importance of monitoring pancreatic and hepatic function in individuals affected by COVID-19.
Descripción
Palabras clave
Citación
Mengual-Moreno, E.; Nava, M.; Manzano, A.; Ariza, D.; D’Marco, L.; Castro, A.; Marquina, M.A.; Hernández, M.; Corredor-Pereira, C.; Checa-Ros, A.; et al. Pancreatic and Hepatic Injury in COVID-19: A Worse Prognosis in NAFLD Patients? Biomedicines 2024, 12, 283. https://doi.org/10.3390/ biomedicines12020283
